Bafna Pharmaceuticals Limited has informed the Exchange about the Re-constitution of Nomination & Remuneration Committee of the Board w.e.f May 20, 2025
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals Limited has re-constituted its Nomination and Remuneration Committee (NRC) with effect from May 20, 2025, following a board meeting on the same day. The reconstituted committee comprises three members: Mrs. Ravichandran Chitra (Non-Executive Independent Director) as Chairperson, Mr. Palamadai Krishnan Sundaresan (Non-Executive Independent Director) as Member, and Mrs. Akila Chintalapati Raju (Non-Executive Non-Independent Director) as Member. The disclosure was made to BSE and NSE under SEBI LODR Regulation 30. This is a routine corporate governance update, with the committee being led by an independent director and having a majority of independent directors.
This is a routine governance disclosure and is unlikely to have any material impact on the stock price or shareholder value. It reflects compliance with SEBI's requirement that the NRC be chaired by an independent director.